In accordance with the Agreement, CTAEX is expected to conduct in 2021 first open field trials with NOMAD plant hosts expressing Thaumatin II, a natural high-intensity non-caloric sweetener of plant origin. The plant biomass will then be transported to a processing facility to purify quantities of Thaumatin II intended for NOMAD’s first consumer market studies in USA.
Thaumatin II has received GRAS (Generally Recognized As Safe) status in USA (FDA GRN 738 and GRN 910) and it thus can be used there commercially as a non-caloric sweetener. NOMAD is aggressively developing regulatory submissions to get Thaumatin II registered in other countries including European Union states.
“We highly appreciate the opportunity to work with CTAEX, a world class organization that conducted field trials and agronomy research and development for all major internationals as well as many small agrobusinesses in Spain. Thaumatin II is a highly promising product with an existing market and huge unmet demands, therefore establishing agronomic conditions for growing Thaumatin-producing crops in Extremadura would allow local farmers to participate in this potentially highly profitable business.”, said Prof. Dr. Yuri Gleba, CEO of NOMAD.
If the project with CTAEX is successful, NOMAD intends to negotiate with CTAEX an agreement to provide industrial amounts of Thaumatin II-containing plant biomass in 2022-24, and later, to help transfer the established cultivation technology to plant growers in Extremadura, Spain, for large-scale contract production.
In addition, NOMAD has also signed an Agreement with the Institute of Plant Cell and Molecular Biology (IBMCP), Valencia, Spain, a unit of Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC) aimed to support NOMAD’s ongoing technical, regulatory and development efforts in Spain.
“NOMAD´s decision to bring its Thaumatin II -producing plants to field trials in Spain is excellent news. They represent not only a remarkable example of cutting-edge biotechnology applied to crops, but also a very promising product that could help to revitalize the agricultural sector in Spain”, said Dr. Orzaez, head of the Crop Biotech Dept at IBMCP. “NOMAD’s expansion plans align with our ongoing efforts in the frame of several EU-funded research projects, which aim to improve plants as biofactories, making them a new driving force in the EU bioeconomy”
CTAEX is a private non-profit R&D Centre located in the region of Extremadura, Spain, founded in 2000 by an association of SMEs, large companies and co-operatives from the agri-food sector. CTAEX is a pioneer in the field of agricultural and food innovation and research in Spain, with the objective of improving the competitiveness of the European agri-food sector from a market-oriented approach.
CTAEX´s Agricultural Department has at its disposal greenhouses and 23 hectares of experimental farms (“ECO” certified among them) equipped with a total irrigation covering. The R&D lines of this area cover a wide variety of experiences such as development and selection of varieties of any crop, research of new crop techniques, new crops exploration, crop protection and alternative agricultural production (integrated and ecological).
Contact info: www.ctaex.com
IBMCP is a research centre jointly owned by the Polytechnic University of Valencia (UPV) and the Spanish Research Council (CSIC). The general objective of the IBMCP is to generate knowledge that enables the design of new crops with an enriched composition and an efficient use of resources, thus satisfying the needs of a sustainable agriculture of the future. The Crop Biotech Department of IBMCP leads ambitious synthetic biology projects, in collaboration with major biotech companies and research institutions, whose objective is to harness the climate-friendly biosynthetic capacity of plants for the biomanufacturing of value-added products such as pharmaceuticals or smart agrochemicals.
Contact info: http://www.ibmcp.upv.es/
Nomad Bioscience GmbH, headquartered in Munich, Germany, is a private biotechnology company developing plant-made biopharmaceuticals, food additives, biomaterials and agronomic traits that address critical unmet needs. NOMAD’s plant-based transient protein expression technologies are licensed to several companies for a broad range of products. NOMAD’s product pipeline consists of several selected protein candidates for human and animal health, food safety and taste modification including plant-made antimicrobial proteins (colicins, lysins and other bacteriocins), antiviral proteins such as griffithsin and other lectins, as well as taste modifying proteins including thaumatins.
The Company is actively seeking corporate partners to help develop and commercialize its products.
Contact info: www.nomadbioscience.com
Nomad Bioscience GmbH
Telefon: +49 (345) 1314-2600